News

Enlarge image

BusinessEU

BIO: debating value in Chicago

25.04.2013 - At the BIO International convention in Chicago, analysts have reported strong performance from the global biotech sector.

They pointed out that there is an urgent need for the industry to demonstrate value of products under development. For 2012, Ernst & Young’s industry report “Beyond borders” reports an increase in revenues by 8% to US$ 89.8bn, with the net income of US$5.2 bn, representing a record high. In Europe, revenues of public biotechs grew 8% to US$ 20.4bn. However, R&D expense decreased by 1 %, which is regarded as an indication that the firms remain in a cost-cutting mode. 

A new survey amongst small and mid-size companies has revealed an “implementation gap” when it comes to gathering evidence to demonstrate the value of products at early stages of development. “Biotech companies can no longer afford to pursue an R&D strategy that only focuses on whether or not their drug works”, said Gautam Jaggi from the Ernst &Young Global Life Sciences Center. Strategic investors and pharma alliance partners would now consider such data to be key drivers of their product and company valuations. “Companies cannot afford not to rethink their R&D approaches and to invest in addressing questions of value”, he said. 

In his talk, Steven Burrill presented similar view. The life science industry insider said in his “supersession”, that value of products is not a constant. “Instead, companies will need to be prepared to prove the value of their products in a world where value is transient, value is payer dependent and value is geographically different“, he said. And, as pressures on pricing intensify, companies will need to be creative in forging new ways to capture value. “Value, like beauty,”  Burrill said, “is in the eye of the beholder.” Companies should have that in mind very early in development.  Celebrating its 20th birthday, BIO International Convention was held in Chicago this year. The most important event for the global biotech industry has attracted over 2000 exhibitors this year, and will see more than 25.000 partnering meetings. 

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/bio-debating-value-in-chicago.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • PROTHENA PLC (IE)38.59 USD-7.15%
  • MEDIGENE (D)8.15 EUR-6.21%
  • ADOCIA (F)56.55 EUR-5.10%

TOP

  • SYNAIRGEN (UK)35.00 GBP45.8%
  • BIOFRONTERA (D)3.24 EUR38.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • SERODUS (N)1.50 NOK-23.9%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1793.3%
  • NICOX (F)8.27 EUR339.9%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.9%
  • BB BIOTECH (D)44.10 EUR-83.1%
  • CYTOS (CH)0.25 CHF-80.3%

No liability assumed, Date: 04.05.2016